Key Highlights

  • Surgery Partners (NASDAQ:SGRY) closed at USD 23.16, down 0.02% in the latest session, and is up 72.41% over one month, the top Mid cap result in a published market data snapshot.
  • HealthSpan Partners, an affiliate of Bon Secours Mercy Health, agreed on October 26, 2026 to buy the company for USD 23.50 per share in cash, a transaction valued at USD 5.7 billion.
  • The shares closed at USD 23.25 on October 26, 2026, up 47.62%, from a prior close of about USD 15.75 (calculated), with a 52-week range of USD 11.41 to USD 23.37.
  • Bain Capital holds roughly 39% of the shares and closing is expected in the first quarter of 2027, so the stock now trades on deal timing more than on growth.

Cash Buyout Announced October 26 Sends Shares Sharply Higher

The jump reflects a Takeover rather than operating momentum. On October 26, 2026, HealthSpan Partners agreed to acquire Surgery Partners (NASDAQ:SGRY) for USD 23.50 per share in cash. The stock finished that session at USD 23.25, up 47.62%, after trading between USD 23.19 and USD 23.25. Published coverage cited Volume of 58.3 million shares against an average of about 3.3 million. At USD 23.16 on the snapshot, the stock sat USD 0.34 below the offer, about 1.5%, on simple arithmetic from two published numbers. Over three months the stock is up 53.96% and over six months 61.81%.

Why a Fixed Cash Price Compresses the Remaining Spread

A fixed cash offer pulls the target shares toward the bid in one session, after which the price trades at a discount for time and risk. The remaining USD 0.34 gap reflects the wait until the first quarter of 2027, the need for approvals and a small chance the deal fails. Bain Capital, with roughly 39% of the stock, is reported to support the transaction, which lowers voting risk. The offer implies a premium of about 49% to the prior close (calculated). The one week change of down 0.41% shows how tightly the price is now anchored to the bid.

Public Float Value, Deal Break Downside and Trading Risks

Published coverage put the Market Value of the publicly traded shares near USD 2.99 billion, inside the USD 2 billion to USD 10 billion mid cap band, with average three month volume of about 3.1 million shares. Upside above the USD 23.50 offer looks limited without a higher bid, while a failed or delayed deal could push the shares back toward pre-bid levels near USD 15.75. The 52-week high of USD 23.37 sits USD 0.21 above the snapshot price (calculated). Regulators could seek changes, the financing is all cash, and any delay stretches the time value. Once arbitrage buyers hold much of the float, trading can thin, and a small number of trades can move the price.

Where Things Stand

Surgery Partners (NASDAQ:SGRY) surged because HealthSpan Partners agreed to buy it for USD 23.50 per share in cash, not because of an operating re-rating. It is the top mid cap gainer over one month in the snapshot, at 72.41%, and trades at USD 23.16, about 1.5% below the offer. With the one week move at down 0.41%, the shares now follow deal timing, expected in the first quarter of 2027, rather than earnings. The move should not be read as a sign it will continue, and a failed deal is the main risk.